RBM3 and nongerminomatous germ cell tumor: In the present series, low expression of RBM3 was a predictor for increased risk of treatment failure in patients with metastatic NSGCT, and one could hypothesize that RBM3 may be a predictor of sensitivity to cisplatin-based treatment also in this type of cancer.